Cairong Li

Dr. Cairong Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
WLWenli Liao
Wenli Liao
ZRZhiwei Rao
Zhiwei Rao
LWLingling Wu
Lingling Wu
YCYong Chen
Yong Chen
CLCairong Li
Cairong Li
Background: Doxorubicin (DOX) is a potent chemotherapeutic agent with limited usage due to its cumulative cardiotoxicity. The Na+/H+ exchanger isoform 1 (NHE1) is a known regulator of oxidative stress, inflammation, and apoptosis. The present study was designed to investigate the possible protective effect of cariporide (CAR), a selective inhibitor of NHE1, against DOX-induced cardiotoxicity in rats.Methods: Male Sprague-Dawley rats were intraperitoneally injected with DOX to induce cardiac toxicity and CAR was given orally for treatment. The injured H9c2 cell model was established by incubation with DOX in vitro. Echocardiography, as well as morphological and ultra-structural examination were performed to evaluate cardiac function and histopathological changes. The biochemical parameters were determined according to the manufacturer’s guideline of kits. ROS were assessed by using an immunofluorescence assay. The serum levels and mRNA expressions of inflammatory cytokines were measured by using ELISA or qRT-PCR. Cardiac cell apoptosis and H9c2 cell viability were tested by TUNEL or MTT method respectively. The protein expressions of Cleaved-Caspase-3, Bcl-2, Bax, Akt, GSK-3β, and Sirt1 were detected by western blot.Results: Treatment with CAR protected against DOX-induced body weight changes, impairment of heart function, leakage of cardiac enzymes, and heart histopathological damage. In addition, CAR significantly attenuated oxidative stress and inhibited the levels and mRNA expressions of inflammatory cytokines (TNF-α, IL-6, IL-18, and IL-1β), which were increased by DOX treatment. Moreover, CAR significantly suppressed myocardial apoptosis and Cleaved-Caspase-3 protein expression induced by DOX, which was in agreement with the increased Bcl-2/Bax ratio. Also, DOX suppressed phosphorylation of Akt and GSK-3β, which was significantly reversed by administration of CAR. Furthermore, CAR treatment prevented DOX-induced down-regulation of Sirt1 at the protein level in vitro and in vivo. Finally, Sirt1 inhibitor reversed the protective effects of CAR, as evidenced by reduced cell viability and Sirt1 protein expression in vitro.Conclusion: Taken together, we provide evidence for the first time in the current study that CAR exerts potent protective effects against DOX-induced cardiotoxicity in rats. This cardio-protective effect is attributed to suppressing oxidative stress, inflammation, and apoptosis, at least in part, through regulation of Akt/GSK-3β and Sirt1 signaling pathway, which has not been reported to date.

20 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
XLXin Liu
Xin Liu
YHYi Hu
Yi Hu
CLCairong Li
Cairong Li
JCJiayu Chen
Jiayu Chen
XLXiaohong Liu
Xiaohong Liu
XXXiming Xu
Ximing Xu
Hepatocellular carcinoma (HCC) is one of the most common cancers and the fourth leading cause of death in men. YEATS domain containing 2 (YEATS2) gene encodes a scaffolding subunit of the ATAC complex. We found that YEATS2 was upregulated in HCC tissues and was associated with a poor prognosis. However, the role of YEATS2 in HCC remains unclear. The purpose of this study was to investigate the effect of YEATS2 on the progression of HCC and to elucidate its related mechanisms. We found that overexpression of YEATS2 promoted tumor cell proliferation, migration, and invasion through the PI3K/AKT signaling pathway and regulation of extracellular matrix. These findings help to understand the role of YEATS2 in HCC, and YEATS2 may become a new target for HCC therapy.

19 July 2024 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
WWWei Wang
Wei Wang
YHYuanyuan Hu
Yuanyuan Hu
NDNing Ding
Ning Ding
JWJiping Wei
Jiping Wei
CLCairong Li
Cairong Li

22 January 2022 in Neurochemistry International
Verified
Journal Article
Closed access
RZRuyi Zhang
Ruyi Zhang
WLWenli Liao
Wenli Liao
KWKe Wu
Ke Wu
LHLiangliang Hua
Liangliang Hua
MWMengyu Wu
Mengyu Wu
FCfei cai
fei cai

4 March 2024 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
SWSiqi Wang
Siqi Wang
XWXin Wang
Xin Wang
LLLi Ling
Li Ling
CLCairong Li
Cairong Li
ZRZhanhong Ren
Zhanhong Ren
Cardiac hypertrophy is one of the key processes in the development of heart failure. Notably, small GTPases and GTPase‑activating proteins (GAPs) serve essential roles in cardiac hypertrophy. RhoGAP interacting with CIP4 homologs protein 1 (RICH1) is a RhoGAP that can regulate Cdc42/Rac1 and F‑actin dynamics. RICH1 is involved in cell proliferation and adhesion; however, to the best of our knowledge, its role in cardiac hypertrophy remains unknown. In the present study, the role of RICH1 in cardiomyocyte hypertrophy was assessed. Cell viability was analyzed using the Cell Counting Kit‑8 assay and cells surface area (CSA) was determined by cell fluorescence staining. Reverse transcription‑quantitative PCR and western blotting were used to assess the mRNA expression levels of hypertrophic marker genes, such as Nppa, Nppb and Myh7, and the protein expression levels of RICH1, respectively. RICH1 was shown to be downregulated in isoproterenol (ISO)‑ or angiotensin II (Ang II)‑treated H9c2 cells. Notably, overexpression of RICH1 attenuated the upregulation of hypertrophy‑related markers, such as Nppa, Nppb and Myh7, and the enlargement of CSA induced by ISO and Ang II. By contrast, the knockdown of RICH1 exacerbated these effects. These findings suggested that RICH1 may be a novel suppressor of ISO‑ or Ang II‑induced cardiomyocyte hypertrophy. The results of the present study will be beneficial to further studies assessing the role of RICH1 and its downstream molecules in inhibiting cardiac hypertrophy.

14 April 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
YZYaning Zheng
Yaning Zheng
SMSheng Ma
Sheng Ma
YCYong Chen
Yong Chen
CLCairong Li
Cairong Li
Background: Diabetic kidney disease (DKD) is a highly significant microvascular complication that arises from diabetes. Therefore, this study aimed to ascertain the traditional risk factors for DKD in type 2 diabetes mellitus (T2DM) in Asia, raising awareness of these risk factors among patients with T2DM. Methods: PubMed, Embase, Web of Science, and Cochrane Library were systematically searched until 13 Mar 2026. Case–control or cohort studies in Asia on the risk factors for DKD were included. Egger’s test and funnel plots were used to assess publication bias. Stata 15 was used for statistical analysis. Results: 7 case-control studies (including 3,312 participants) and 17 cohort studies (including 8,735 participants) were included. All the included studies were of high quality according to the Newcastle-Ottawa Scale (NOS). Systolic blood pressure (SBP), hypertension, glycosylated hemoglobin (HbA1c), waist-to-hip ratio (WHR), fasting blood glucose (FBG), uric acid (UA), creatinine (Cr), age and diabetes duration were risk factors for DKD in T2DM. Diabetic retinopathy (DR) was closely associated with DKD, and this association was also evident in subgroups defined by pathological diagnosis. SBP was a risk factor in both the clinical diagnosis group and the pathological diagnosis group. Conclusions: This meta-analysis preliminarily demonstrates that SBP, hypertension, HbA1c, WHR, FBG, UA, Cr, age, diabetes duration and DR are associated with DKD in Asia. SBP and DR are associated with renal biopsy-confirmed DKD. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard , identifier CRD42024529789.